CN Patent

CN113164505A — 用于治疗丙型肝炎病毒的高活性药物组合

Assigned to Atea Pharmaceuticals Inc · Expires 2021-07-23 · 5y expired

What this patent protects

提供了化合物1或其药学上可接受的盐(例如化合物1‑A)和化合物2或其药学上可接受的盐(例如化合物2‑A)的组合以治疗丙型肝炎感染的宿主；及其药物组合物和剂型，包括其固体剂型。

USPTO Abstract

提供了化合物1或其药学上可接受的盐(例如化合物1‑A)和化合物2或其药学上可接受的盐(例如化合物2‑A)的组合以治疗丙型肝炎感染的宿主；及其药物组合物和剂型，包括其固体剂型。

Drugs covered by this patent

Patent Metadata

Patent number: CN113164505A
Jurisdiction: CN
Classification: —
Expires: 2021-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Atea Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.